Log in with your email address username.


Attention doctorportal newsletter subscribers,

After December 2018, we will be moving elements from the doctorportal newsletter to MJA InSight newsletter and rebranding it to Insight+. If you’d like to continue to receive a newsletter covering the latest on research and perspectives in the medical industry, please subscribe to the Insight+ newsletter here.

As of January 2019, we will no longer be sending out the doctorportal email newsletter. The final issue of this newsletter will be distributed on 13 December 2018. Articles from this issue will be available to view online until 31 December 2018.

Irritable bowel syndrome, dyspepsia and other chronic disorders of gastrointestinal function

- Featured Image

New diagnostic criteria and knowledge are changing how patients are treated

In this issue of the MJA, we highlight a number of topics of major interest in gastroenterology, including Barrett’s oesophagus,1 the risks of proton pump inhibitors,2 biosimilars for inflammatory bowel disease,3 and gluten intolerance.4

Chronic or recurrent gastrointestinal symptoms are frequently encountered in primary care.5 Most patients who present with gastrointestinal symptoms do not, however, have inflammatory bowel disease, cancer or another sinister pathology, but rather an unexplained or functional gastrointestinal disorder (FGID).6 The best known FGID is the irritable bowel syndrome (IBS), but there are other FGIDs that need to be recognised, as there is effective management that can improve people’s lives.69 The expert consensus is that clinicians should strive to make a positive clinical diagnosis of an FGID on the basis of the patient’s history, and not simply wait for negative test results.6 In 2016, new international guidelines on diagnosis were published, the updated Rome (IV) Criteria (